The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
JITC launched two new sections in 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy," and submit today!
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 9.913 on June 29, 2020. JITC’s Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 8% percent of all journals published in the categories of oncology and immunology. Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2019 citations accumulated for JITC manuscripts published in 2017 and 2018. Other valuable journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles submitted and accepted in 2020.
For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. It is becoming apparent that the ‘ground glass’ infiltrative appearance seen on CT scans from patients with COVID-19 with pneumonitis is reminiscent of imaging from patients with immune checkpoint inhibitor (ICI)-induced pneumonitis.1 2 Additionally, elevated interleukin-6 (IL-6) is a hallmark inflammatory signature seen in serum of patients with severe COVID-19 acute respiratory distress.3 Many of us have experience with the administration of immune-modulatory agents, which is why the cancer immunotherapy community is poised to contribute to the current fight against COVID-19.
Interleukin-2 (IL-2) plays a pivotal role in immune homeostasis due to its ability to stimulate numerous lymphocyte subsets including natural killer (NK) cells, effector CD4+ and CD8+ T cells, and regulatory T cells (Tregs). Low concentrations of IL-2 induce signaling through the high-affinity IL-2 receptor (IL-2R) comprised of IL-2Rα, IL-2Rβ, and common γ chain (γc), preferentially expressed on Tregs. Higher concentrations of IL-2 are necessary to induce signaling through the intermediate-affinity IL-2R, composed of IL-2Rβ and γc, expressed on memory CD8+ T cells and NK cells. Recombinant human IL-2 (rhIL-2) is approved for treatment of metastatic melanoma and renal cell carcinoma (RCC), but adverse events including capillary leak syndrome, potentially mediated through interaction with the high-affinity IL-2R, limit its therapeutic use. Furthermore, antitumor efficacy of IL-2 may also be limited by preferential expansion of immunosuppressive Tregs. ALKS 4230 is an engineered fusion protein comprised of a circularly-permuted IL-2 with the extracellular domain of IL-2Rα, designed to selectively activate effector lymphocytes bearing the intermediate-affinity IL-2R.
This online meeting will connect you with all the recent research on how the tumor microenvironment influences cancer, and how its manipulation can provide potential means for immunotherapy. You just need to have access to the internet and you can join ...
Hi J. Gonzalo, Thanks for the registration details. I have confirmed your slot and I will keep you posted with the further updates. If any of your colleagues (Up to 10 people only) also wish to participate kindly ask them to send their details ...
Hi, I am interested to attend the webinar. Thanks in advance J. Gonzalo Ocejo-Vinyals, MD, PhD Immunogenetics and Histocompatibility Laboratory Santander, Spain ------------------------------ J. Gonzalo Ocejo-Vinyals MD, PhD Immunologist Medical Staff ...
Hi Dr. Satti , Thanks for the registration details. I have confirmed your slot and I will keep you posted with the further updates. If any of your colleagues (Up to 10 people only) also wish to participate kindly ask them to send their details ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com